141699-59-4

Basic information

• Product Name: 1-Boc-4-methanesulfonyloxypiperidine
• Synonyms: N-(TERT-BUTOXYCARBONYL)PIPERIDIN-4-YL MESYLATE;N-BOC-4-(methanesulfonyloxy)piperidine;1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate;1-Boc-methanesulfonyl-piperdine;4-[(Methylsulphonyl)oxy]piperidine, N-BOC protected;tert-Butyl 4-[(methylsulphonyl)oxy]piperidine-1-carboxylate;1-Piperidinecarboxylicacid,4-[(Methylsulfonyl)oxy]-,1,1-diMethylethylester;4-Methanesulfonyloxypiperidin-1-carboxylic acid tert-butyl ester
• CAS NO: 141699-59-4
• Molecular Formula: C₁₁H₂₁NO₅S
• Molecular Weight: 279.35
• EINECS: 200-081-4
• Product Categories: pharmacetical
• Mol File: 141699-59-4.mol
• Article Data: 130

Chemical Properties

• Melting Point: 193-195 °C
• Boiling Point: 407.186 °C at 760 mmHg
• Flash Point: 200.059 °C
• Appearance: /
• Density: 1.223 g/cm³
• Vapor Pressure: 7.69E-07mmHg at 25°C
• Refractive Index: 1.5
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -3.02±0.40(Predicted)
• CAS DataBase Reference: 1-Boc-4-methanesulfonyloxypiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-methanesulfonyloxypiperidine(141699-59-4)
• EPA Substance Registry System: 1-Boc-4-methanesulfonyloxypiperidine(141699-59-4)

Safety Data

• Hazard Codes: T
• Statements: 25-20/21/22
• Safety Statements: 45-24/25-23
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 141699-59-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C11H21NO5S/c1-11(2,3)16-10(13)12-7-5-9(6-8-12)17-18(4,14)15/h9H,5-8H2,1-4H3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 24424-99-5 di-tert-butyl dicarbonate 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 7542-23-6 piperazine hydrochloride 
• 329794-15-2 2-(4-chloromethyl-pyridin-2-ylamino)-thiazole-5-carbonitrile 
• 179051-57-1 4-(2-naphthylsulphonyl)piperidine 
• 75-75-2 methanesulfonic acid 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24608-52-4 tert-butyl chloroformate 
• 911410-37-2 1-(4-hydroxypiperidin-1-yl)-2,2-dimethylpropan-1-one 

Downstream Products

• 863257-51-6 tert-butyl 4-(4-phenyl-1H-imidazole-1-yl)piperidine-1-carboxylate 
• 208245-69-6 4-methylsulfanylpiperidine-1-carboxylic acid tert-butyl ester 
• 1027671-54-0 tert-butyl 4-(3-bromophenyl)sulfanylpiperidine-1-carboxylate 
• 1027143-39-0 4-(2-bromo-phenylsulfanyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 188527-03-9 4-(4-bromophenylsulfanyl)piperidine-1-carboxylic acid tert-butyl ester 
• 233281-74-8 tert-butyl 4-[(3-hydroxymethyl-4-nitro)phenoxy]piperidine-1-carboxylate 
• 193276-49-2 (R)-(+)-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-<5,6>cyclohepta<1,2-b>pyridin-11-yl)-1-piperidine 
• 226398-48-7 tert-butyl 4-[(4-fluorophenyl)sulfanyl]piperidine-1-carboxylate 
• 877399-74-1 tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 226399-44-6 tert-Butyl 4-[(4-Hydroxyphenyl)sulfanyl]-1-piperidinecarboxylate 
• 444605-55-4 1,1-dimethylethyl 4-[(2-bromophenyl)oxy]-1-piperidinecarboxylate 
• 1005402-49-2 4-[4-(3-methyl-6-oxo-1-pyridin-2-yl-1,6-dihydropyridazin-4-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester 
• 321337-40-0 4-[4-(2-hydroxy-ethyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester 
• 138227-74-4 1-tert-butyloxycarbonyl-4-(4-nitro-3-methylphenyloxy)piperidine 

Relevant articles and documents

Synthesis and Characterization of N-(4-(Piperidin-4-ylsulfonyl) phenyl)5-vinylpyrimidin-2-amine

Target product N-(4-(piperidin-4-ylsulfonyl)phenyl)5-vinylpyrimidin-2- amine (13) was synthesized using 6-oxopyran-3-carbaldehyde (M1) and 4-hydroxypiperidine (M2) as starting materials by a series of nucleophilic substitution and oxidation. Different aci

Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis

Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments.

Copper-Catalyzed Cross-Coupling between Alkyl (Pseudo)halides and Bicyclopentyl Grignard Reagents

The development of a copper-catalyzed cross-coupling between primary and secondary (pseudo)halides and bicyclopentyl Grignard reagents is reported. Highly strained bicyclopentanes can be cross-coupled with a large panel of primary alkyl mesylates and secondary alkyl iodides. The catalytic system is simple and cheap, and the reaction is general and chemoselective.